

The SIA Report

Q2
2025

Beyond Standard Coverage: The Essential ABCs of Property & Casualty Insurance



By David A. Robertson
JD*, CFP®
Partner

For individuals and families with significant assets, protecting what you've built requires more than standard insurance policies. Property and Casualty (P&C) insurance is a cornerstone of comprehensive wealth protection, yet its nuances are often misunderstood. As climate-related risks increase—with events like California wildfires underscoring potential exposure—understanding and optimizing your P&C coverage is not just prudent—it's critical. This guide outlines the ABCs, to help you navigate the fundamentals.

A is for Assets

Protecting Your Valuable Property

The 'Property' component of P&C insurance safeguards physical assets against damage or loss from various perils such as fire, theft, vandalism, and natural disasters. For many, "property" includes not just a primary residence but also estates, custom homes, worldwide vacation properties, and valuable collections.

Understanding Coverage Needs for Unique Assets

Standard homeowners policies often have sub-limits for valuable items like jewelry, art, antiques, or wine collections, which are typically far below their actual worth. A more comprehensive policy can address this gap by offering:

- **Higher Coverage Limits:** Sufficient limits for custom homes, extensive estates, and multiple properties.
- **Replacement Cost Coverage:** Rebuilding or replacing property to its original standard without depreciation, with extended replacement cost offering protection.
- **Scheduled Personal Property:** Specific "scheduling" or "floating" high-value items like art, jewelry, and electronics at their appraised value.
- **Coverage for Other Structures:** Protection for guesthouses, custom pools, and other structures.
- **Luxury and Collector Vehicles:** Specialized coverage for high-end cars, classic vehicles, yachts, and private aircraft.

B is for Being Liable Shielding Yourself with Casualty Insurance

The 'Casualty' portion of P&C insurance protects against liability, covering legal costs, settlements, and judgments if you're found responsible for injury or property damage. Personal liability risks increase with multiple properties, domestic staff, hosting events, nonprofit board involvement, and owning assets like pools, watercraft, or exotic cars.

Why Standard Limits Fall Short

Liability limits in standard homeowners (typically \$300,000 - \$500,000) or auto policies are often grossly inadequate to protect substantial assets. A major lawsuit could potentially exceed these limits.

The Crucial Role of Umbrella/Excess Liability Policies

An umbrella or excess liability policy adds an extra layer of protection, activating once the limits of your primary policies (home, auto, watercraft) are exhausted.

C is for Comprehensive & Custom Coverage Tailoring Protection to Your Unique Needs

Standard insurance products are designed for the average consumer and often do not adequately address the unique risks of affluent individuals and families. In today's complex environment, off-the-shelf coverage may fall short.

Ensuring your property and liability coverage is comprehensive, customized, and insured by a carrier familiar with your needs is key to protecting your lifestyle, legacy, and loved ones. To make certain you know your ABCs, a periodic review and analysis of all your P&C coverage by a qualified professional is paramount with today's fluid insurance markets. Partner with your advisor to design a strategy tailored to your unique needs.



Navigating Uncertainty: Is Healthcare's Weak Start to 2025 an Opportunity for Investors?



By Carlos Sanabria
CFA®
Investment Specialist

As of the end of May, healthcare was one of the worst performing sectors of the US stock market year-to-date, driven by policy uncertainty under the new administration and potential reforms targeting prescription drug pricing. Does this represent an attractive entry point for investors, or is there more pain to come for the sector?

This article looks at key factors influencing the sector: significant spending adjustments within the Department of Health and Human Services (HHS), the ripple effects of tariffs on medical device supply chains, and ongoing executive efforts to manage drug pricing.

Deep Dive: Factors Shaping the 2025 Healthcare Landscape

Spending Adjustments and Workforce Realignment

The Department of Health and Human Services (HHS) is navigating a period of significant fiscal restructuring. The administration's budget proposals for 2026 aim to streamline operations and reduce federal expenditure, which has direct implications for various facets of the U.S. healthcare system.

Recent announcements indicate substantial changes, including a proposed 26.2% reduction in HHS's discretionary spending compared to 2025. This translates to a potential \$40 billion cut, bringing the discretionary budget to approximately \$80.4 billion from around \$121 billion. A significant component of this strategy involves workforce reductions, with plans for around 10,000 employee layoffs through voluntary separation programs, projected to save taxpayers \$1.8 billion annually. Specific agencies like the Food and Drug Administration (FDA) could see its workforce decrease by approximately 3,500 full-time employees. Furthermore, HHS has been directed to reduce spending on contracts by 35% across all its divisions, including the Centers for Disease Control and Prevention (CDC), National Institutes of Health (NIH), and the FDA. These agencies face potential funding cuts of 44% (CDC), 40% (NIH), and 19% (FDA), respectively.

The stated rationale for these measures includes enhancing efficiency and combating fraud, waste, and abuse. However,

these adjustments raise concerns about potential impacts on public health infrastructure, the pace of medical research, and the nation's leadership in scientific innovation, potentially delaying breakthroughs in areas like mRNA technology and AI-driven diagnostics. For investors, this environment may introduce short-term volatility, especially for companies heavily reliant on federal grants and funding, such as those supplying labs or research organizations. Conversely, an increased focus on efficiency could create opportunities for companies adept at navigating a shifting funding landscape.

The Impact of Tariffs on Medical Device Supply Costs

International trade policies, particularly tariffs, continue to exert pressure on the medical device manufacturing sector. With a significant portion of medical devices used in the U.S. being manufactured abroad (with heavy reliance on countries like China, Mexico, and Canada), import duties have a direct impact on supply chain costs and, ultimately, healthcare affordability.

The current tariff landscape includes a universal 10% baseline tariff on many imports, with potentially higher rates on specific goods or imports from particular countries, such as China, Mexico, and Canada. These tariffs affect a wide array of critical medical supplies and equipment, including syringes, medical masks, respirators, gloves, diagnostic machines, and surgical robots. The U.S. medical equipment market, valued at \$197.8 billion in 2023, is thus highly sensitive to these cost pressures.

The consequences for medical device manufacturers are multifaceted. Increased input costs can squeeze profit margins or be passed on to healthcare providers and patients, potentially leading to higher healthcare expenses. For example, some health systems anticipate annual cost increases ranging from \$10 million to \$25 million due to tariffs. While some larger manufacturers are exploring strategies like supply chain diversification and investing in domestic production, the overall sector faces uncertainty. For investors, this dynamic highlights the importance of companies with resilient supply chains and the potential for opportunities in domestic manufacturing or innovative cost-mitigation technologies.

Executive Actions and the Pursuit of Lower Drug Prices

Efforts to manage and reduce prescription drug prices remain a prominent feature of the healthcare policy landscape. Various executive actions and legislative initiatives aim to enhance affordability and accessibility of medications for American consumers.

Key measures include establishing Most-Favored-Nation drug pricing for consumers to buy high-cost drugs direct from manufacturers, implementing caps on out-of-pocket expenses for Medicare beneficiaries, and enforcing penalties for drug price increases that outpace inflation. Enhanced price transparency is also a focus. While specific new executive orders detailing sweeping changes for 2025 might not be at the forefront of recent announcements, the underlying administrative goal of reducing healthcare costs, including pharmaceuticals, continues. The administration's broader agenda of reducing fraud, waste, and abuse within

HHS programs may also indirectly influence drug pricing strategies and enforcement against Health Insurers and Pharmacy Benefits Managers (PBMs).

For pharmaceutical companies, these policies can exert pressure on revenues and profit margins. However, the industry is also responding with heightened focus on innovation, particularly in specialty drugs and personalized medicine, where new therapies can command premium pricing and address unmet medical needs. This dynamic encourages a shift towards value-based products. Administration policies may also benefit US based drug manufacturers, at the expense of foreign rivals.

We are keenly monitoring both the potential regulatory headwinds and the robust pipeline of innovative treatments that continue to drive value in the pharmaceutical sector.

Overall Outlook: A Bullish Stance Tempered by Caution

Despite the outlined challenges, the broader outlook for the healthcare sector in 2025 remains largely positive. This optimism is underpinned by several factors:

- **Demographic Tailwinds:** Aging populations and the rising prevalence of chronic diseases create sustained demand for healthcare services and products.
- **Technological Advancement:** Breakthroughs in areas like gene therapy, AI-driven diagnostics, treatments for obesity and diabetes, and telehealth continue to open new markets and improve patient outcomes.
- **Attractive Valuations:** Following periods of underperformance or market correction, certain healthcare sub-sectors may offer attractive entry points for investors.
- **Mergers and Acquisitions:** Increased M&A activity and private equity investment signal confidence in the sector's long-term prospects.

While our positive outlook is supported by strong fundamentals like persistent demand, ongoing innovation, and attractive valuations in certain areas, it is crucial to maintain a balanced perspective. Policy uncertainty related to potential administrative changes and their impact on federal programs also warrants careful attention. A balanced approach, focusing on companies with strong fundamentals, innovative pipelines, and adaptive business models, will be key to navigating this complex but promising environment.

"I believe successful wealth management is the result of an ongoing collaboration between investor and advisor, built upon trust and maintained according to the highest standards of integrity and knowledge."

Brian D. Holmes
MS, CFP®, AIF®
CEO

ABOUT SIA

Signature Investment Advisors® (SIA) is a Registered Investment Advisor firm offering investment management solutions that are tailored to meet the unique needs of affluent individuals and organizations. In partnership with your wealth manager, we bring our combined experience, knowledge, and high level of service to provide a dynamic process that can meet your investment objectives and goals.



2025 Tax Brackets

The tax items for tax year 2025 of greatest interest to many taxpayers include the following dollar amounts:

Married – Filing Jointly

The standard deduction for married couples filing jointly for tax year 2025 rises to \$30,000, up \$800 from the prior year.

Married – Filing Separately / Single

For single taxpayers and married individuals filing separately, the standard deduction rises to \$15,000 for 2025, up \$400.

Head of Household

For heads of households, the standard deduction will be \$22,500 for tax year 2025, up \$600.

Marginal Rates

For tax year 2025, the top tax rate remains 37% for individual single taxpayers with incomes greater than \$626,350 (\$751,600 for married couples filing jointly).

The other rates are:

35% for incomes over \$250,525 (\$501,050 for married couples filing jointly)

32% for incomes over \$197,300 (\$394,600 for married couples filing jointly)

24% for incomes over \$103,350 (\$206,700 for married couples filing jointly)

22% for incomes over \$48,475 (\$96,950 for married couples filing jointly)

12% for incomes over \$11,925 (\$23,850 for married couples filing jointly)

The lowest rate is 10% for incomes of \$11,925 or less (\$23,850 or less for married couples filing jointly)

Source: Internal Revenue Service. SIA is not engaged in rendering legal, accounting, or tax services. We recommend that all investors seek out the services of competent professionals in any of the aforementioned areas. This tax information does not constitute personalized financial or tax advice. Each individual's financial situation is unique and you should consult a tax professional to understand how these tax brackets apply to your specific situation.

SIA

SIGNATURE INVESTMENT ADVISORS®

Century City, CA

2121 Avenue of the Stars, Suite 1600
Los Angeles, CA 90067

T 888 349 3241

F 310 855 3955

SignatureIA.com

Signature Investment Advisors, LLC (SIA) is an SEC-registered investment adviser; however, such registration does not imply a certain level of skill or training and no inference to the contrary should be made. The information contained herein is the opinion of SIA and is subject to change at any time. It is not intended as tax, legal, or financial advice, and it may not be relied on for the purpose of avoiding any federal tax penalties. You are encouraged to seek such advice from your professional tax, legal, or financial advisor. The content is derived from sources believed to be accurate but not guaranteed to be. For a complete listing of sources please contact SIA. Neither the information presented, nor any opinion expressed constitutes a solicitation for the purchase or sale of any security. Past performance is not indicative of future results. Every investment program has the potential for loss as well as gain. There is a risk of loss from an investment in securities, including the risk of loss of principal. Different types of investments involve varying degrees of risk, and there can be no assurance that any specific investment will be profitable or suitable for a particular investor's financial situation or risk tolerance. Securities offered through Signature Estate Securities, LLC, member FINRA/SIPC. Investment advisory services offered through SIA, 2121 Avenue of the Stars, Suite 1600, Los Angeles, CA 90067 (888) 349-3241.

Professional Designations: AIF® - Accredited Investment Fiduciary®. Issued by the Center for Fiduciary Studies. Candidates must complete the AIF training program, pass the final certification exam, and fulfill the continuing education requirement of 6 hours per year. CFA® - Chartered Financial Analyst®. Issued by the CFA Institute. A highly respected designation earned by investment professionals who successfully complete three parts of the CFA exam. CFA charter holders must meet several requirements, including having a bachelor's degree or equivalent education/work experience, passing the CFA Program, and fulfilling the continuing education requirement. CFP® - CERTIFIED FINANCIAL PLANNER®. Issued by the Certified Financial Planner Board of Standards, Inc. A professional designation for financial planners who meet requirements such as having a bachelor's degree, completing the CFP education program, passing the CFP certification exam, and fulfilling the continuing education requirement. MS - Master of Science in Financial Planning is a graduate degree for the financial services industry offered by many institutions across the country. For more details on the Professional Designations listed above, including description, minimum requirements, and ongoing education requirements, please contact SIA at (888) 349-3241 or visit signatureia.com/disclosures.

ID# 062725 - 8120868 / 7572259